Cardlytics (NASDAQ:CDLX) Posts Earnings Results, Misses Expectations By $0.08 EPS

Cardlytics (NASDAQ:CDLX) released its earnings results on Wednesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.08), Zacks reports. The firm had revenue of $56.09 million during the quarter, compared to analyst estimates of $54.46 million. Cardlytics had a negative net margin of 44.36% and a negative return on equity of 370.98%.

Here are the key takeaways from Cardlytics’ conference call:

• Cardlytics says its 2025 reset delivered discipline and tech modernization — reporting full-year Adjusted EBITDA of $10.1M, Q4 Adjusted EBITDA of $8.5M, faster feature delivery (+20%) and lower infrastructure costs (-40%).
• The company ended its Bank of America relationship and faces content restrictions from a large FI, which the firm says is the primary driver of weak Q1 2026 guidance (billings down ~41%–35% YoY) and an expected negative Adjusted EBITDA of -$7.5M to -$3.5M.
• Management highlights strong advertiser traction — particularly in grocery, convenience and fashion/luxury — with Q4 U.K. revenue up >35% YoY, a 60% QoQ increase in new business wins, and large spend increases from key advertisers.
• The planned sale of Bridg to PAR Technology is expected to close this month and, per management, will bolster liquidity (they intend to liquidate received PAR shares to pay down the credit facility) and eliminate non-core costs.

Cardlytics Stock Performance

Shares of CDLX stock opened at $0.94 on Wednesday. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 2.87. Cardlytics has a 12-month low of $0.66 and a 12-month high of $3.28. The business’s 50 day moving average is $0.92 and its two-hundred day moving average is $1.34. The company has a market capitalization of $51.69 million, a P/E ratio of -0.48 and a beta of 1.03.

Wall Street Analysts Forecast Growth

CDLX has been the topic of several research analyst reports. Bank of America reiterated an “underperform” rating on shares of Cardlytics in a research note on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Cardlytics in a research note on Monday, December 29th. Finally, Evercore set a $1.00 price target on shares of Cardlytics in a research report on Friday, March 6th. Two equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cardlytics has an average rating of “Reduce” and a consensus target price of $1.75.

Insider Activity at Cardlytics

In other news, CEO Amit Gupta sold 45,159 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $0.93, for a total transaction of $41,997.87. Following the completion of the transaction, the chief executive officer directly owned 659,644 shares of the company’s stock, valued at $613,468.92. This represents a 6.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 117,875 shares of company stock valued at $113,022 in the last three months. 4.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Cardlytics

A number of institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd raised its position in Cardlytics by 143.5% during the second quarter. XTX Topco Ltd now owns 85,971 shares of the company’s stock worth $141,000 after acquiring an additional 50,663 shares during the period. Marshall Wace LLP acquired a new stake in shares of Cardlytics in the second quarter valued at about $59,000. Jane Street Group LLC grew its position in shares of Cardlytics by 263.0% in the second quarter. Jane Street Group LLC now owns 162,427 shares of the company’s stock valued at $267,000 after purchasing an additional 117,687 shares during the period. Private Advisor Group LLC purchased a new stake in shares of Cardlytics during the third quarter worth about $272,000. Finally, UBS Group AG increased its stake in shares of Cardlytics by 112.5% during the third quarter. UBS Group AG now owns 458,066 shares of the company’s stock worth $1,113,000 after purchasing an additional 242,536 shares in the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.

At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.